From 1998 until 2006 Richard covered Major Pharmaceuticals as a Senior Research Analyst at Sanford Bernstein, receiving numerous top rankings including first team selection by Institutional Investor, being twice ranked first for drug stock selection by Bloomberg, and in 2006 being ranked among the top 20 stock pickers globally across all industries, also by Bloomberg. Previously, Richard was a member of senior management at Roche, responsible for Roche’s commercial interactions with large organized buyers such as hospitals, hospital purchasing groups, managed-care organizations and governments. His responsibilities also included those areas of the company which define and support account interactions, namely account management, customer marketing, pricing, contract administration, pharmacoeconomics, and distribution. During his seven years at Roche, Richard also served as the head of Business Development and Strategic Planning, and as product director for the company’s injectable anesthetics. He earned a doctorate in Veterinary Medicine from North Carolina State University in 1988 and a master’s of Public and Private Management from Yale University in 1991. Richard is the author of Health and Capital, a unique perspective on the American health care system and prospects for its reform (www.healthandcapital.com)
Scott Hinds is an experienced economist, having earned his M.S. from the University of North Carolina, where he taught Microeconomics to both graduate and undergraduate students. His degree includes a concentration in Microeconomic Theory and extensive experience in complex econometric techniques. Scott’s graduate research focused on information asymmetries and the game theoretical foundations of herd behavior. His work has been published in Nature Reviews Drug Discovery and the Handbook of Public Finance. Scott has also worked in investment banking with Lehman Brothers and as a strategic consultant with AVOS Life Sciences. As an equity capital markets financial analyst, Scott worked on numerous IPOs, convertible and PIPE offerings for a range of healthcare, biotechnology and industrial companies. Immediately prior to joining SSR Health, Scott worked as a strategic consultant specializing in large scale quantitative engagements for major pharmaceutical clients.